Welcome to Dragonfly Biosciences, Europe’s leading premium retailer of Cannabidiol (CBD).
A research-fuelled and community-minded company, Dragonfly controls the process from seed to sale, guaranteeing the highest and most consistent product quality. We work strictly within the frontiers of current legislation and operate with total transparency, keeping our fields, processing facility, laboratories and products open to consumers.
Currently offering a range of CBD health and lifestyle products, Dragonfly aims to expand its business and product range in line with legal changes in Europe.
As demand grows for CBD health supplements, we will continue to be the go-to producer and supplier of Cannabidiol for both businesses and consumers.
Guaranteed accurate concentration (%) of CBD
Produced under stringent control and tested by independent, accredited labs
Organically certified product
GUARANTEED CUSTOMER CARE
Customer service that can help you before, during and after the purchase
All our products are tested in third-party laboratories, as well as our own to ensure consistency and quality across the board. Dragonfly works under Good Manufacturing Practices (GMP). Our product line is standardised to contain specific quantities of cannabinoids including, CBD, CBD-a and CBG. We guarantee that our products are 100% organic. Click here to read more…
Radost is an entrepreneur and experienced businesswoman, based in Sofia.
Equipped with a law degree, she spent her early years as head of the Legal Department at Sofia Municipality, responsible for all large-scale urban development, architecture, and infrastructure-focused projects.
Radost has developed a series of solar farms, a successful TV production company and now is dedicated to building Dragonfly Biosciences.
Chris is a serial entrepreneur and investor. With experience in both media and health-related industries.
Chris is acting CEO; having previously been involved in Wellbeing Network, where he also served as a CEO.
In 1991, Chris founded Chello Zone Holdings (also known as Zone Vision Networks) an England-based TV company. Chris served as President; he developed and expanded Zone Vision Networks worldwide.
Chello Zone was sold to Liberty Global and then in 2014 sold to AMC Networks as part of the Chellomedia sale for more than $1.0bn
Chris also ran Sapphire Media, which was sold to (LFP) Larry Flynt Productions and Zone Studios which was sold to BTI.
Regan is a Chartered Accountant with over 20 years of experience in the media industry.
Regan has spent 4 years at NBCUniversal where he served as VP Finance in the Emerging Markets and International Corporate divisions.
Previously, Regan spent 8 years at Chello Zone where he served as CFO supporting the worldwide expansion and the eventual sale of Chellomedia to AMC Networks.
Prior to that, Regan spent 8 years at the BBC where he held various senior finance roles.
Regan qualified with Moore Stephens in 1994
Hannah spent her early years as an analyst at The RSA Group and then later at Goodlord. After topping the Management Tripos at Kings College London, Hannah studied for a Masters in Management at the London School of Economics.
Promoted from Business Development Associate to the Head of Business Development within a year, Hannah is passionate about CBD and is dedicated to developing Dragonfly Biosciences into a successful business.
Mark has over 30 years experience in the media industry; film, television and music.
Initially a kidnap and ransom broker at Lloyds of London, he then became one of the original team members of Henson International Television, the creators of The Muppet Show.
After several productions in TV, music and film, he put together a group that raised US$250m to acquire the International Library Rights to titles in and the Hallmark Channel. This was subsequently acquired by NBCUniversal in 2007.
Subsequently, Mark has multiple investments in digital media.
Paul has more than 25 years leadership experience in the pharmaceutical industry. After spending 14 years at GlaxoSmithKline (GSK), including a stint as the General Manager of Europe, Paul later became the Executive Vice President of Worldwide Commercial Operations at Gilead Sciences Inc. He also spent four years working at Arthur Anderson and is now the board director of several biotech companies, as well as being a Fellow of the UK Chartered Institute of Management Accountants.
Olav is an international pharmaceutical executive with particular expertise in clinical development, out-licensing, commercialisation and the marketing of new therapeutics. Currently the Chief Executive Officer of ReNeuron PLC., Olav holds an impressive track record as the previous CEO at Clavis Pharma ASA, a listed biotechnology company; the head of the UK commercial operations at Novartis; and the head of the global bio-logistics franchise at UCB Pharma. He has a Bachelor of Business Administration from Hofstra University, USA, and an MBA from the IESE Business School.
Dominik is a seasoned finance operative and media entrepreneur. Based in Poland, his career includes stints as Chief Investment Officer at Kulczyk Investments and Chief Executive Officer at Cyfrowy Polsat SA, CPS:WSE. He also ran his own television company – Studio Meg – and holds a Master’s degree from the Department of Environmental Studies and Environmental Protection Faculty at the Wroclaw Technical University.
Dermot is a chartered accountant and global executive with over 20 years’ experience leading complex, high-growth, multi-national organizations. He has been Chief Executive Officer of Zone Vision Networks Ltd. since January 2002 and played a key role in building and selling the (US$1million) company. Fabled for his operational control, commercial creativity and strategic planning, Dermott has helped to grow brands such as CNBC, Discovery, Animal Planet, Food Network, CBS, Extreme Sports, Outdoor Channel, MGM and AMC.
Alex boasts a wealth of experience with the Virgin Group. Currently the team principal of the Virgin Racing Formula E, he has been both director of Virgin Management and CEO for Virgin Galactic, playing a pivotal role alongside Richard Branson in leading the company towards its first commercial space flight – now only two years away. Alex is a trained Aviation pilot and holds additional experience in property development.
EWA MELANIA GRYT
Ewa is one of the most recognised authorities in the Polish Hemp business. After studying Cannabis Sativa L. in depth back in 2004, she opened a General Hemp Marketing Company. She is a distributor of several international hemp brands and has two of her own: Dobre Konopie and Konopie W Kichini. Ewa holds an MA in Biology & Animal Sciences from the University of Agriculture, Krakow.
Sayed is an investor and senior consultant at MYAH capital, a strategic consultancy firm he founded to assist businesses entering new markets. He has worked in a range of project management and accountancy roles at Sainsbury’s, TK Maxx and WorldCom. He also holds experience in launching new brands such as Beats by Dr Dre in the UK.
DR SAOIRSE O’SULLIVAN
Saoirse brings 15 years of cannabinoid wisdom to the Dragonfly board. Currently serving as Associate Professor at the University of Nottingham, her research is centred in on the endocannabinoid system, with a particular focus on the role it plays in diabetes and obesity. Since 2016, she has been named Young Investigator of the Year by the International Cannabinoid Research Society and acted as a source of expertise for numerous BBC documentaries. A seasoned academic, she will keep us at the cutting edge of new research findings.
DR BRIAN O’CONNOR
Brian is a consultant in respiratory medicine, specialising in allergies and airway diseases. He is fully active in clinical research and has published in highly regarded peer-reviewed journals, edited numerous books and written chapters on Asthma and Chronic Pulmonary Disease (COPD). He is one of the founders of Queen Anne Street Medical Centre.
DR JULIAN KARADJOV
Julian has worked for the Bulgarian Academy of Sciences for nearly 20 years, developing an in-depth knowledge of cannabis in the process. One of the most recognised authorities on pharmaceuticals in Bulgaria, he has written two books – including Cannabis: Science and Politics – and is currently working on a paper exploring the synthesis and biomedical testing of a new class of synthetic cannabinoids.
In association with